RLMD
Relmada Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.77 / 10
Netural
Liquidity flow evaluation: 7.55/10 demonstrating robust fund flow characteristics. Optimistic Small and Medium patterns are mitigated by pessimistic overall, block, Large, and Extra-large indicators, pointing to positive flow perspective. The analyst community expresses overwhelmingly bullish analyst consensus with strong conviction. Ratings composition: Buy(100.0%) representing 1 analyst views, supported by 0.00 historical weighted rating.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-23
InstitutionLeerink Partners
Times predicted1
Historical Win Rate0.0%
Is money flowing into or out of RLMD?
- RLMD holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.77/10 (Netural).
